<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970550</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A01013-38</org_study_id>
    <nct_id>NCT04970550</nct_id>
  </id_info>
  <brief_title>Vaccination Against SARS-Cov2 (COVID-19) in Chronic Inflammatory Rheumatism and Factors Determining Its Decision.</brief_title>
  <acronym>VACCI-RIC</acronym>
  <official_title>Vaccination Against SARS-Cov2 in Chronic Inflammatory Rheumatism and Factors Determining Its Decision.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Nord Franche-Comte</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Nord Franche-Comte</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis and spondyloarthritis (ankylosing spondylitis and psoriatic arthritis&#xD;
      mainly) are chronic inflammatory rheumatism (RIC), frequently onset in young adults. The&#xD;
      prevalence is respectively 0.3 to 0.8% and 0.4%. or about 600,000 people. The &quot;basic&quot;&#xD;
      treatments (DMARDs), essential to control the progression of the disease, are classified into&#xD;
      csDMARDs (chemical), the first of which is methotrexate, or bDMARDs (biological). These&#xD;
      treatments are immunomodulators and there is an increased risk of severe infection under&#xD;
      these therapies. Several vaccinations are therefore recommended by learned societies in&#xD;
      patients receiving these treatments, in order to prevent certain infectious risks.In the&#xD;
      current pandemic context, the vaccination of these patients against SARS-Cov2 is a major&#xD;
      issue in their management and is recommended by the French society of rheumatology. However,&#xD;
      many patients express doubts about this vaccination or refuse it. The factors associated with&#xD;
      the vaccination will are not known. Better identifying them would make it possible to adapt&#xD;
      the information to be given to our patients to promote their adherence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">August 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the desire to be vaccinated against SARS-CoV2</measure>
    <time_frame>At inclusion</time_frame>
    <description>Percentage of patients with RIC and treated with DMARDs who favor vaccination against SARS-CoV2 ; determined with a questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Factors associated with the desire for vaccination against SARS-CoV2</measure>
    <time_frame>At inclusion</time_frame>
    <description>Identify the factors associated with the desire for vaccination against SARS-CoV2 ; determined with a questionnaire</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Spondyloarthritis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non intervention</intervention_name>
    <description>Non intervention</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A questionnaire is completed by the patient with the investigator during the medical&#xD;
        consultation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ambulatory patients&#xD;
&#xD;
          -  Men or women of any age&#xD;
&#xD;
          -  Follow-ups for chronic inflammatory rheumatism such as rheumatoid arthritis or&#xD;
             spondyloarthritis&#xD;
&#xD;
          -  Treated with methotrexate or biotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not treated with biotherapy or methotrexate.&#xD;
&#xD;
          -  Patients in whom the assessment could not be performed reliably&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Nord Franche-Comté</name>
      <address>
        <city>Trévenans</city>
        <zip>90400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elodie BOUVIER</last_name>
      <phone>0384983570</phone>
      <email>elodie.bouvier@hnfc.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS COV 2 vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Fever</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

